Biopharmaceutical company Zedira has followed up funding from High-Tech Gruenderfonds and R-Biopharm by licensing development of its celiac disease treatment to Dr Falk.
Germany-based biotechnology company Zedira licensed development and marketing rights for ZED-101, its chemical blocker for treating celiac disease, to pharmaceuticals company Dr Falk on Friday.
High-Tech Gruenderfonds, the venture capital firm backed by the German government and several Germany-based conglomerates, led Zedira’s series A round in October 2007, investing €500,000 ($350,000).
High-Tech Gruenderfonds was later joined by clinical diagnostics and food analysis firm R-Biopharm in funding Zedira’s series B round in May last year.
As part of the…
